Oncologist Makes the Case That Cancer Doctors Should Recommend Cannabis to Patients

An oncologist argues that cannabis, already proven safe and effective for chemotherapy nausea and appetite loss, should be recommended by cancer doctors for its ability to simultaneously address pain, mood, sleep, and appetite without the need for multiple prescriptions.

Abrams, Donald I·Current treatment options in oncology·2019·Moderate EvidenceReview
RTHC-01894ReviewModerate Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Cannabis analgesic effects are supported by the best clinical evidence. THC is already FDA-approved for chemotherapy nausea (since 1986) and AIDS wasting (since 1992). Significant preclinical anticancer activity exists but clinical evidence is absent. A single intervention addressing nausea, appetite, pain, mood, and sleep is a valuable addition to palliative care. Evidence for serious harms from cannabis inhalation is scant.

Key Numbers

THC approved for chemotherapy nausea since 1986, appetite stimulation since 1992. Pain relief has the strongest clinical evidence. Multiple symptom domains addressed by one intervention: nausea, appetite, pain, mood, sleep.

How They Did This

Narrative review by an oncologist examining the evidence for cannabis in cancer care, covering pain, nausea, appetite, mood, sleep, and potential anticancer properties.

Why This Research Matters

Cancer patients often take multiple medications for different symptoms. This review argues that cannabis could address several symptoms simultaneously, reducing polypharmacy and improving quality of life for patients with limited time.

The Bigger Picture

Despite federal restrictions limiting research, the author argues oncologists have enough evidence to recommend cannabis and should gather "first-hand evidence" by incorporating it into practice. This represents a growing voice within mainstream oncology.

What This Study Doesn't Tell Us

Narrative review by a known cannabis medicine advocate. Anticancer evidence is preclinical only. Recommendations go beyond what some systematic reviews support. Risk tolerance may differ by patient population.

Questions This Raises

  • ?Can oncologists recommend cannabis in good conscience despite limited RCT data?
  • ?Would formal clinical trials change practice, or is real-world evidence sufficient?
  • ?How should oncologists balance symptom relief against uncertain long-term effects?

Trust & Context

Key Stat:
Cannabis addresses five symptom domains simultaneously (nausea, appetite, pain, mood, sleep) - an unusual advantage over single-target medications.
Evidence Grade:
Moderate - expert opinion piece grounded in clinical evidence and personal experience, but represents one perspective rather than systematic analysis.
Study Age:
Published in 2019.
Original Title:
Should Oncologists Recommend Cannabis?
Published In:
Current treatment options in oncology, 20(7), 59 (2019)
Authors:
Abrams, Donald I(6)
Database ID:
RTHC-01894

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Should cancer patients use cannabis?

This oncologist argues yes, noting cannabis can simultaneously address pain, nausea, appetite loss, mood problems, and sleep difficulties. THC has been FDA-approved for chemotherapy nausea since 1986, and pain relief has the strongest clinical evidence.

Can cannabis cure cancer?

Despite significant preclinical evidence of anticancer activity, there is currently no clinical evidence that cannabis cures cancer in humans. This oncologist recommends cannabis for symptom management and palliative care rather than as a cancer treatment.

Read More on RethinkTHC

Cite This Study

RTHC-01894·https://rethinkthc.com/research/RTHC-01894

APA

Abrams, Donald I. (2019). Should Oncologists Recommend Cannabis?. Current treatment options in oncology, 20(7), 59. https://doi.org/10.1007/s11864-019-0659-9

MLA

Abrams, Donald I. "Should Oncologists Recommend Cannabis?." Current treatment options in oncology, 2019. https://doi.org/10.1007/s11864-019-0659-9

RethinkTHC

RethinkTHC Research Database. "Should Oncologists Recommend Cannabis?" RTHC-01894. Retrieved from https://rethinkthc.com/research/abrams-2019-should-oncologists-recommend-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.